Aliskiren, enalapril, or aliskiren and enalapril in heart failure

New England Journal of Medicine

Volumn 374, Issue 16, 2016, Pages 1521-1532

  McMurray, John J V ^a   Krum, Henry ^c   Abraham, William T ^d   Dickstein, Kenneth ^e,f   Køber, Lars V ^g   Desai, Akshay S ^h   Solomon, Scott D ^h   Greenlaw, Nicola ^b   Ali, M Atif ⁱ   Chiang, Yanntong ⁱ   Shao, Qing ⁱ   Tarnesby, Georgia ⁱ   Massie, Barry M ^j  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d OHIO STATE UNIVERSITY   (United States)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF BERGEN   (Norway)

^g Rigshospitalet   (Denmark)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; CREATININE; ENALAPRIL; AMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMARIC ACID DERIVATIVE; RENIN;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; AGED; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

AGED; AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RENIN; STROKE VOLUME; TREATMENT FAILURE;

EID: 84964455478     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1514859     Document Type: Article

References (22)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
3. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.
4. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
5. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
6. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
7. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
8. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
9. Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007; 9: 1120-7.
10. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
11. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9.
12. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011; 13: 107-14.
13. Krum H, McMurray JJ, Abraham WT, et al. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. Eur J Heart Fail 2015; 17: 1075-83.
14. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35: 1245-55.
15. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.
16. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-35.
17. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-3.
18. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ. Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. Eur J Heart Fail 2013; 15: 1205-7.
19. Maggioni AP, Greene SJ, Fonarow GC, et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013; 34: 3117-27.
20. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
21. Timmis A. Neprilysin inhibition for heart failure. N Engl J Med 2014; 371: 2336.
22. Swedberg K, Borer JS, Pitt B, Pocock S, Rouleau J. Challenges to data monitoring committees when regulatory authorities intervene. N Engl J Med 2016;374:1580-4.